Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose KX-01 is a novel dual inhibitor of Src and tubulin. Unlike previous Src inhibitors that failed to show clinical benefit during treatment of breast cancer, KX-01 can potentially overcome the therapeutic limitations of current Src inhibitors through inhibition of both Src and tubulin. The present study further evaluates the activity and mechanism of KX-01 in vitro and in vivo. Materials and Methods The antitumor effect of KX-01 in triple negative breast cancer (TNBC) cell lines was determined by MTT assay. Wound healing and immunofluorescence assays were performed to evaluate the action mechanisms of KX-01. Changes in the cell cycle and molecular changes induced by KX-01 were also evaluated. A MDA-MB-231 mouse xenograft model was used to demonstrate the in vivo effects. Results KX-01 effectively inhibited the growth of breast cancer cell lines. The expression of phospho- Src and proliferative-signaling molecules were down-regulated in KX-01–sensitive TNBC cell lines. In addition, migration inhibition was observed by wound healing assay. KX-01– induced G2/M cell cycle arrest and increased the aneuploid cell population in KX-01–sensitive cell lines. Multi-nucleated cells were significantly increased after KX-01 treatment. Furthermore, KX-01 effectively delayed tumor growth in a MDA-MB-231 mouse xenograft model. Conclusion KX-01 effectively inhibited cell growth and migration of TNBC cells. Moreover, this study demonstrated that KX-01 showed antitumor effects through the inhibition of Src signaling and the induction of mitotic catastrophe. The antitumor effects of KX-01 were also demonstrated in vivo using a mouse xenograft model.
Abstract
Purpose KX-01 is a novel dual inhibitor of Src and tubulin. Unlike previous Src inhibitors that failed to show clinical benefit during treatment of breast cancer, KX-01 can potentially overcome the therapeutic limitations of current Src inhibitors through inhibition of both Src and tubulin. The present study further evaluates the activity and mechanism of KX-01 in vitro and in vivo. Materials and Methods The antitumor effect of KX-01 in triple negative breast cancer (TNBC) cell lines was determined by MTT assay. Wound healing and immunofluorescence assays were performed to evaluate the action mechanisms of KX-01. Changes in the cell cycle and molecular changes induced by KX-01 were also evaluated. A MDA-MB-231 mouse xenograft model was used to demonstrate the in vivo effects. Results KX-01 effectively inhibited the growth of breast cancer cell lines. The expression of phospho- Src and proliferative-signaling molecules were down-regulated in KX-01–sensitive TNBC cell lines. In addition, migration inhibition was observed by wound healing assay. KX-01– induced G2/M cell cycle arrest and increased the aneuploid cell population in KX-01–sensitive cell lines. Multi-nucleated cells were significantly increased after KX-01 treatment. Furthermore, KX-01 effectively delayed tumor growth in a MDA-MB-231 mouse xenograft model. Conclusion KX-01 effectively inhibited cell growth and migration of TNBC cells. Moreover, this study demonstrated that KX-01 showed antitumor effects through the inhibition of Src signaling and the induction of mitotic catastrophe. The antitumor effects of KX-01 were also demonstrated in vivo using a mouse xenograft model.
참고문헌 (28)
- Cleator S, "Triple-negative breast cancer : therapeutic options", Lancet Oncol, 8, pp.235~244 (2007)
- Tryfonopoulos D, "Src : a potential target for the treatment of triple-negative breast cancer", Ann Oncol, 22, pp.2234~2240 (2011)
- Hiscox S, "Src inhibitors in breast cancer therapy", Expert Opin Ther Targets, 12, pp.757~767 (2008)
- Finn RS, "Targeting Src in breast cancer", Ann Oncol, 19, pp.1379~1386 (2008)
- Chen T, "Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3", Mol Cancer Ther, 4, pp.217~224 (2005)
- Finn RS, "Dasatinib as a single agent in triple-negative breast cancer : results of an open-label phase 2 study", Clin Cancer Res, 17, pp.6905~6913 (2011)
- Gucalp A, "Phase II trial of saracatinib(AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer", Clin Breast Cancer, 11, pp.306~311 (2011)
- Carey L, "Triple-negative breast cancer: disease entity or title of convenience?", Nat Rev Clin Oncol, 7, pp.683~692 (2010)
- Castedo M, "Cell death by mitotic catastrophe : a molecular definition", Oncogene, 23, pp.2825~2837 (2004)
- Gardner MK, "Microtubule catastrophe and rescue", Curr Opin Cell Biol, 25, pp.14~22 (2013)
- Topham CH, "Mitosis and apoptosis: how is the balance set", Curr Opin Cell Biol, 25, pp.780~785 (2013)
- Vakifahmetoglu H, "Death through a tragedy : mitotic catastrophe", Cell Death Differ, 15, pp.1153~1162 (2008)
- Vitale I, "Mitotic catastrophe : a mechanism for avoiding genomic instability", Nat Rev Mol Cell Biol, 12, pp.385~392 (2011)
- Anbalagan M, "Peptidomimetic Src", pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER, HER2-negative tumor xenografts, pp.Mol Cancer Ther, 2012[DOI]
- Anbalagan M, "KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer", Breast Cancer Res Treat, 132, pp.391~409 (2012)
- Antonarakis ES, "A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bonemetastatic castration-resistant prostate cancer", Cancer Chemother Pharmacol, 71, pp.883~892 (2013)
- Naing A, "A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket-directed SRC inhibitor, in patients with advanced malignancies", Invest New Drugs, 31, pp.967~973 (2013)
- Liu T, "Targeting SRC and tubulin in mucinous ovarian carcinoma", Clin Cancer Res, 19, pp.6532~6543 (2013)
- 강소영, "TGF-β Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells", Cancer Research and Treatment, 47(1), pp.101~109 (2015), 대한암학회[DOI]
- Min A, "RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib", Mol Cancer Ther, 12, pp.865~877 (2013)
- Nam HJ, "Antitumor activity of saracatinib(AZD0530), a c-Src", Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer, 2013, pp.12, 16~26
- Macurek L, "Regulation of microtubule nucleation from membranes by complexes of membrane-bound gamma-tubulin with Fyn kinase and phosphoinositide 3-kinase", Biochem J, 416, pp.421~430 (2008)
- Kasahara K, "Src signaling regulates completion of abscission in cytokinesis through ERK", MAPK activation at the midbody, 2007, pp.282, 5327~5339
- Nakayama Y, "c-Src but not Fyn promotes proper spindle orientation in early prometaphase", J Biol Chem, 287, pp.24905~24915 (2012)
- Soeda S, "v-Src causes delocalization of Mklp1, Aurora B, and INCENP from the spindle midzone during cytokinesis failure", Exp Cell Res, 319, pp.1382~1397 (2013)
- Park AY, "Role of focal adhesion kinase Ser-732 phosphorylation in centrosome function during mitosis", J Biol Chem, 284, pp.9418~9425 (2009)
- Rea K, "EGFR", MEK, CDK5-dependent integrin-independent FAK phosphorylated on serine 732 contributes to microtubule depolymerization and mitosis in tumor cells, pp.Cell Death Dis, 2013[DOI]
- Chee CE, "Phase II study of dasatinib(BMS-354825)in patients with metastatic adenocarcinoma of the pancreas", Oncologist, 18, pp.1091~1092 (2013)